HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes

Journal of Virology

Volumn 86, Issue 6, 2012, Pages 3393-3397

  Doria Rose, Nicole A ^a   Louder, Mark K ^a   Yang, Zhongjia ^a   O'Dell, Sijy ^a   Nason, Martha ^a   Schmidt, Stephen D ^a   McKee, Krisha ^a   Seaman, Michael S ^b   Bailer, Robert T ^a   Mascola, John R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIGEN BINDING; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; EPITOPE MAPPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; VIRUS CELL INTERACTION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84863269120     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06745-11     Document Type: Article

References (41)

1. Baba TW, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200 -206.
2. Balazs AB, et al. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481:81- 84.
3. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J. 2007. HIV-1 subtypeAenvelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21:693-702.
4. Burton DR, et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
5. Burton DR, Stanfield RL, Wilson IA. 2005. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U. S. A. 102:14943-14948.
6. Chong H, et al. 2008. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. J. Acquir. Immune Defic. Syndr. 47:535-543.
7. Chou T-C, Martin N. 2007. CompuSyn for drug combinations and for general dose-effect analysis, and user's guide. ComboSyn, Inc., Paramus, NJ.
8. Chou TC. 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440-446.
9. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
10. Corti D, et al. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5:e8805.
11. Hessell AJ, et al. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15: 951-954.
12. Johnson PR, et al. 2009. Vector-mediated gene transfer engenders longlived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15:901-906.
13. Keele BF, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
14. Kulkarni SS, et al. 2009. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology 385:505-520.
15. Li M, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108 -10125.
16. Li M, et al. 2006. Genetic and neutralization properties of subtype C human immunodeficiencyvirus type1molecular env clonesfromacuteandearly heterosexually acquired infections in Southern Africa. J. Virol. 80:11776-11790.
17. Mascola JR, et al. 1997. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71:7198 -7206.
18. Mascola JR, Montefiori DC. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413- 444.
19. Mascola JR, et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
20. McElrath MJ, Haynes BF. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542-554.
21. McLellan JS, et al. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336 -343.
22. Mofenson LM. 2011. Prevention of mother-to-child HIV-1 transmission- why we still need a preventive HIV immunization strategy. J. Acquir. Immune Defic. Syndr. 58:359 -362.
23. Muster T, et al. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642- 6647.
24. Pejchal R, et al. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103.
25. Potts BJ, et al. 1993. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. Virology 197:415-419.
26. Safrit JT, et al. 2004. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 35:169 -177.
27. Scheid JF, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637.
28. Seaman MS, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for neutralizing antibody assessment. J. Virol. 84: 1439-1452.
29. Shu Y, et al. 2007. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25:1398 -1408.
30. Trkola A, et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615- 622.
31. Trkola A, et al. 2008. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J. Virol. 82:1591- 1599.
32. Trkola A, et al. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
33. Veazey RS, et al. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9:343-346.
34. Verrier F, Nadas A, Gorny MK, Zolla-Pazner S. 2001. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J. Virol. 75:9177-9186.
35. Walker LM, et al. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
36. Walker LM, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
37. Webb JL. 1963. Effects of more than one inhibitor, p 488-512. Enzyme and metabolic inhibitors, vol 1. Academic Press, New York, NY.
38. Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
39. Wu X, et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602.
40. Zhou T, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811- 817.
41. Zwick MB, et al. 2001. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 75:12198 -12208.